Strategies to reduce the use of blood products: A US perspective

Current Opinion in Anaesthesiology

Volumn 25, Issue 1, 2012, Pages 50-58

  Shander, Aryeh ^a,b   Javidroozi, Mazyar ^a  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

anemia; autotransfusion; blood loss; patient blood management; transfusion

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIANEMIC AGENT; APROTININ; CYANOCOBALAMIN; FIBRIN; FIBRIN GLUE; FOLIC ACID; HEMOGLOBIN; HEMOSTATIC AGENT; IRON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TRANEXAMIC ACID;

ANEMIA; ANTICOAGULANT THERAPY; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD SALVAGE; BLOOD TRANSFUSION; CLINICAL DECISION MAKING; DEVICES; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; IRON THERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PHLEBOTOMY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STANDARD; UNITED STATES;

ANEMIA; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; HUMANS; PATIENT SAFETY; RISK FACTORS; UNITED STATES;

EID: 84855791844     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32834dd282     Document Type: Review

References (111)

1. Isbister JP, Shander A, Spahn DR, et al. Adverse blood transfusion outcomes: establishing causation. Transfus Med Rev 2011; 25:89-101.
2. Spahn DR, Shander A, Hofmann A, et al. More on transfusion and adverse outcome: its time to change. Anesthesiology 2011; 114:234-236.
3. Shander A, Fink A, Javidroozi M, et al. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev 2011; 25:232-246.
4. Toner RW, Pizzi L, Leas B, et al. Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy 2011; 9:29-37.
5. Carter MC, Wilson J, Redpath GS, et al. Donor recruitment in the 21st century: Challenges and lessons learned in the first decade. Transfus Apher Sci 2011; 45:31-43.
6. Benjamin RJ, Whitaker BI. Boom or bust? Estimating blood demand and supply as the baby boomers age. Transfusion 2011; 51:670-673.
7. Desalvo F, Verlicchi F, Tomasini I. An estimate of future transfusion needs in the province of Ravenna made on the basis of Italian national statistics and past consumption. Blood Transfus 2011; 4:1-6.
8. Barr PJ, Donnelly M, Morris K, et al. The epidemiology of red cell transfusion. Vox Sang 2010; 99:239-250.
9. Drackley A, Newbold KB, Paez A, et al. Forecasting Ontarios blood supply and demand. Transfusion 2011. [Epub ahead of print]
10. Spinella PC, Doctor A, Blumberg N, et al. Does the storage duration of blood products affect outcomes in critically ill patients? Transfusion 2011; 51:1644-1650.
11. Vamvakas EC. Meta-analysis of clinical studies of the purported deleterious effects of old (versus fresh) red blood cells: are we at equipoise? Transfusion 2010; 50:600-610.
12. Fontaine MJ, Chung YT, Erhun F, et al. Age of blood as a limitation for transfusion: potential impact on blood inventory and availability. Transfusion 2010; 50:2233-2239.
13. Pereira A. Modeling the effect of reducing maximum shelf life on red blood cell availability. Transfusion 2011; 51:662-663.
14. Rogers MA, Blumberg N, Heal JM, et al. Utilization of blood transfusion among older adults in the United States. Transfusion 2011; 51:710-718.
15. Bennett-Guerrero E, Zhao Y, OBrien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010; 304:1568-1575.
16. Gombotz H, Hofman A, Rehak P, et al. Patient blood management (part 2) - Practice: the 3 pillars. Anasthesiol Intensivmed Notfallmed Schmerzther 2011; 46:466-474.
17. Welsby I, Crow J, Bandarenko N, et al. A clinical prediction tool to estimate the number of units of red blood cells needed in primary elective coronary artery bypass surgery. Transfusion 2010; 50:2337-2343.
18. Gombotz H, Rehak PH, Shander A, et al. Blood use in elective surgery: the Austrian benchmark study. Transfusion 2007; 47:1468-1480. (Pubitemid 47101072)
19. Grey DE, Smith V, Finlayson J. Iron studies and red cell transfusion in cardiothoracic and orthopaedic surgical patients: a retrospective audit at a tertiary hospital. Vox Sang 2011. [Epub ahead of print]
20. Goodnough LT, Maniatis A, Earnshaw P, et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106:13-22.
21. Bohlius J, Tonia T, Schwarzer G. Twist and shout: one decade of metaanalyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol 2011; 125:55-67.
22. Goodnough LT, Shander AS. Erythropoiesis stimulating agents, blood transfusion, and the practice of medicine. Am J Hematol 2010; 85:835-837.
23. Weinhandl ED, Gilbertson DT, Collins AJ. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Am J Nephrol 2011; 34:298-308.
24. Vadhan-Raj S, Zhou X, Sizer K, et al. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist 2010; 15:1359-1369.
25. Khalafallah A, Dennis A, Bates J, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med 2010; 268:286-295.
26. Na HS, Shin SY, Hwang JY, et al. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion 2011; 51:118-124.
27. Auerbach M, Silberstein PT, Webb RT, et al. Darbepoetin alfa 300 or 500 mg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010; 85:655-663.
28. Krafft A, Breymann C. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study. J Obstet Gynaecol Res 2011; 37:119-124.
29. Serrano-Trenas JA, Ugalde PF, Cabello LM, et al. Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. Transfusion 2011; 51:97-104.
30. Jacob M, Smedira N, Blackstone E, et al. Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. Circulation 2011; 123:577-583.
31. Thaler HW, Frisee F, Korninger C. Platelet aggregation inhibitors, platelet function testing, and blood loss in hip fracture surgery. J Trauma 2010; 69:1217-1220.
32. Ravn HB, Lindskov C, Folkersen L, et al. Transfusion requirements in 811 patients during and after cardiac surgery: a prospective observational study. J Cardiothorac Vasc Anesth 2011; 25:36-41.
33. Hofer CK, Zollinger A, Ganter MT. Perioperative assessment of platelet function in patients under antiplatelet therapy. Expert Rev Med Devices 2010; 7:625-637.
34. West KL, Adamson C, Hoffman M. Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature. J Neurosurg 2011; 114:9-18.
35. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011; 117:6091-6099.
36. Salisbury AC, Reid KJ, Alexander KP, et al. Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med 2011; 171:1646-1653.
37. Ogawa S, Szlam F, Chen EP, et al. A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion 2011. [Epub ahead of print]
38. Cotton BA, Faz G, Hatch QM, et al. Rapid thromboelastography delivers realtime results that predict transfusion within 1 h of admission. J Trauma 2011; 71:407-417.
39. Nascimento B, Al Mahoos M, Callum J, et al. Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography. Transfusion 2011. [Epub ahead of print]
40. Afshari A, Wikkelso A, Brok J, et al. Thromboelastography (TEG) or thromboelastometry (ROTEM) tomonitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev 2011; CD007871.
41. Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg 2010; 140:1117-1124.
42. Wang SC, Shieh JF, Chang KY, et al. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc 2010; 42: 2590-2593.
43. Sniecinski RM, Chen EP, Makadia SS, et al. Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth 2010; 24:959-963.
44. Vonk AB, Meesters MI, Schats J, et al. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery. Interact Cardiovasc Thorac Surg 2011; 12:135-139.
45. Martin K, Gertler R, Liermann H, et al. Switch from aprotinin to {varepsilon}- aminocaproic acid: impact on blood loss, transfusion, and clinical outcome in neonates undergoing cardiac surgery. Br J Anaesth 2011. [Epub ahead of print]
46. Schindler E, Photiadis J, Sinzobahamvya N, et al. Tranexamic acid: an alternative to aprotinin as antifibrinolytic therapy in pediatric congenital heart surgery. Eur J Cardiothorac Surg 2011; 39:495-499.
47. Massicotte L, Denault AY, Beaulieu D, et al. Aprotinin versus tranexamic acid during liver transplantation: impact on blood product requirements and survival. Transplantation 2011; 91:1273-1278.
48. Ralley FE, Berta D, Binns V, et al. One intraoperative dose of tranexamic acid for patients having primary hip or knee arthroplasty. Clin Orthop Relat Res 2010; 468:1905-1911.
49. Lin PC, Hsu CH, Chen WS, et al. Does tranexamic acid save blood in minimally invasive total knee arthroplasty? Clin Orthop Relat Res 2011; 469:1995-2002.
50. Noordin S, Waters TS, Garbuz DS, et al. Tranexamic acid reduces allogeneic transfusion in revision hip arthroplasty. Clin Orthop Relat Res 2011; 469:541-546.
51. Sukeik M, Alshryda S, Haddad FS, et al. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011; 93:39-46.
52. Wang G, Xie G, Jiang T, et al. Tranexamic acid reduces blood loss after offpump coronary surgery: a prospective, randomized, double-blind, placebocontrolled study. Anesth Analg 2011. [Epub ahead of print]
53. Adler Ma SC, Brindle W, Burton G, et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2011; 25:26-35.
54. Goobie SM, Meier PM, Pereira LM, et al. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology 2011; 114:862-871.
55. Dadure C, Sauter M, Bringuier S, et al. Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study. Anesthesiology 2011; 114:856-861.
56. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377:1096-1101; 1101.
57. Williams-Johnson JA, McDonald AH, Strachan GG, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2). A randomised, placebocontrolled trial. West Indian Med J 2010; 59:612-624.
58. Henry DA, Carless PA, Moxey AJ, et al. Antifibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; CD001886.
59. Raghunathan K, Connelly NR, Kanter GJ. Epsilon-aminocaproic acid and clinical value in cardiac anesthesia. J Cardiothorac Vasc Anesth 2011; 25:16-19.
60. Berman M, Cardone D, Sharples L, et al. Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients. Ann Thorac Surg 2010; 90:1432-1436.
61. Koster A, Schirmer U. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol 2011; 24:92-97.
62. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011; 154:516-522.
63. Lin Y, Stanworth S, Birchall J, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011; CD005011.
64. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154:529-540.
65. Chavez-Tapia NC, faro-Lara R, Tellez-Avila F, et al. Prophylactic activated recombinant factor VII in liver resection and liver transplantation: systematic review and meta-analysis. PLoS One 2011; 6:e22581.
66. Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010; 69:489-500.
67. Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791-1800.
68. Schochl H, Posch A, Hanke A, et al. High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. Scand J Clin Lab Invest 2010; 70:453-457.
69. Thorarinsdottir HR, Sigurbjornsson FT, Hreinsson K, et al. Effects of fibrinogen concentrate administration during severe hemorrhage. Acta Anaesthesiol Scand 2010; 54:1077-1082.
70. Spotnitz WD, Burks S. State-of-the-art review: hemostats, sealants, and adhesives. II. Update as well as how and when to use the components of the surgical toolbox. Clin Appl Thromb Hemost 2010; 16:497-514.
71. Chalmers RT, Darling Iii RC, Wingard JT, et al. Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular surgical procedures. Br J Surg 2010; 97:1784-1789.
72. Wong J, Abrishami A, El BH, et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am 2010; 92:2503-2513.
73. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg 2009; 88:1520-1526.
74. Allen DS, Marso SP, Lindsey JB, et al. Comparison of bleeding complications using arterial closure device versus manual compression by propensity matching in patients undergoing percutaneous coronary intervention. Am J Cardiol 2011; 107:1619-1623.
75. Atik FA, Svensson LG, Blackstone EH, et al. Less invasive versus conventional double-valve surgery: a propensity-matched comparison. J Thorac Cardiovasc Surg 2011; 141:1461-1468.
76. Biffi R, Luca F, Pozzi S, et al. Operative blood loss and use of blood products after full robotic and conventional low anterior resection with total mesorectal excision for treatment of rectal cancer. J Robot Surg 2011; 5:101-107.
77. Kordan Y, Barocas DA, Altamar HO, et al. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int 2010; 106:1036-1040.
78. Bonatti J, Schachner T, Wiedemann D, et al. Factors influencing blood transfusion requirements in robotic totally endoscopic coronary artery bypass grafting on the arrested heart. Eur J Cardiothorac Surg 2011; 39:262-267.
79. Sutherland DE, Perez DS, Weeks DC. Robot-assisted simple prostatectomy for severe benign prostatic hyperplasia. J Endourol 2011; 25:641-644.
80. Li B, Wen Y, Liu D, et al. The effect of knee position on blood loss and range of motion following total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc 2011. [Epub ahead of print]
81. Ervens J, Marks C, Hechler M, et al. Effect of induced hypotensive anaesthesia vs isovolaemic haemodilution on blood loss and transfusion requirements in orthognathic surgery: a prospective, single-blinded, randomized, controlled clinical study. Int J Oral Maxillofac Surg 2010; 39:1168-1174.
82. Morrison CA, Carrick MM, Norman MA, et al. Hypotensive resuscitation strategy reduces transfusion requirements and severe postoperative coagulopathy in trauma patients with hemorrhagic shock: preliminary results of a randomized controlled trial. J Trauma 2011; 70:652-663.
83. Fromes Y, Daghildjian K, Caumartin L, et al. A comparison of low vs conventional-dose heparin for minimal cardiopulmonary bypass in coronary artery bypass grafting surgery. Anaesthesia 2011; 66:488-492.
84. Ovrum E, Tangen G, Tollofsrud S, et al. Heparinized cardiopulmonary bypass circuits and low systemic anticoagulation: an analysis of nearly 6000 patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2011; 141:1145-1149.
85. Yilmaz A, Sjatskig J, van Boven WJ, et al. Combined coronary artery bypass grafting and aortic valve replacement with minimal extracorporeal closed circuit circulation versus standard cardiopulmonary bypass. Interact Cardiovasc Thorac Surg 2010; 11:754-757.
86. Kuss O, von Salviati B, Borgermann J. Off-pump versus on-pump coronary artery bypass grafting: a systematic review and meta-analysis of propensity score analyses. J Thorac Cardiovasc Surg 2010; 140:829-835; 835.
87. Adams ES, Longhurst CA, Pageler N, et al. Computerized physician order entry with decision support decreases blood transfusions in children. Pediatrics 2011; 127:e1112-e1119.
88. Ansari S, Szallasi A. Blood management by transfusion triggers: when less is more. Blood Transfus 2011; 4:1-6.
89. Baer VL, Henry E, Lambert DK, et al. Implementing a program to improve compliance with neonatal intensive care unit transfusion guidelines was accompanied by a reduction in transfusion rate: a prepost analysis within a multihospital healthcare system. Transfusion 2011; 51:264-269.
90. Gallagher-Swann M, Ingleby B, Cole C, et al. Improving transfusion practice: ongoing education and audit at two tertiary speciality hospitals in Western Australia. Transfus Med 2011; 21:51-56.
91. Tavares M, DiQuattro P, Nolette N, et al. Reduction in plasma transfusion after enforcement of transfusion guidelines. Transfusion 2011; 51:754-761.
92. Carless PA, Henry DA, Carson JL, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2010; CD002042.
93. Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010; 304:1559-1567.
94. Cooper HA, Rao SV, Greenberg MD, et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol 2011; 108:1108-1111.
95. Carson JL, Kuriyan M. What should trigger a transfusion? Transfusion 2010; 50:2073-2075.
96. Frasca D, hyot-Fizelier C, Catherine K, et al. Accuracy of a continuous noninvasive hemoglobin monitor in intensive care unit patients. Crit Care Med 2011; 39:2277-2282.
97. Bailey SM, Hendricks-Munoz KD, Mally P. Splanchnic-cerebral oxygenation ratio as a marker of preterm infant blood transfusion needs. Transfusion [Epub ahead of print]
98. Watanabe N, Suzuki T, Ogawa K, et al. Five-year study assessing the feasibility and safety of autologous blood transfusion in pregnant Japanese women. J Obstet Gynaecol Res 2011. [Epub ahead of print]
99. Parvizi J, Chaudhry S, Rasouli MR, et al. Who needs autologous blood donation in joint replacement? J Knee Surg 2011; 24:25-31.
100. Singbartl G. Preoperative autologous blood donation: clinical parameters and efficacy. Blood Transfus 2011; 9:10-18.
101. Jarnagin WR, Gonen M, Maithel SK, et al. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. Ann Surg 2008; 248:360-369.
102. Fischer M, Matsuo K, Gonen M, et al. Relationship between intraoperative fluid administration and perioperative outcome after pancreaticoduodenectomy: results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management. Ann Surg 2010; 252:952-958.
103. Carless PA, Rubens FD, Anthony DM, et al. Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; CD004172.
104. Carless PA, Henry DA, Moxey AJ, et al. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2010; CD001888.
105. Shantikumar S, Patel S, Handa A. The role of cell salvage autotransfusion in abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2011; 42:577-584.
106. Esper SA, Waters JH. Intra-operative cell salvage: a fresh look at the indications and contraindications. Blood Transfus 2011; 9:139-147.
107. Bower MR, Ellis SF, Scoggins CR, et al. Phase II comparison study of intraoperative autotransfusion for major oncologic procedures. Ann Surg Oncol 2011; 18:166-173.
108. Masud F, Larson-Pollock K, Leveque C, et al. Establishing a culture of blood management through education: a quality initiative study of postoperative blood use in CABG patients at Methodist DeBakey Heart & Vascular Center. Am J Med Qual 2011; 26:349-356.
109. McMillan D, Brady P, Foot C, et al. The team focus on improving blood transfusion. J Extra Corpor Technol 2011; 43:65-67.
110. Moskowitz DM, McCullough JN, Shander A, et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? Ann Thorac Surg 2010; 90:451-458.
111. Netzer G, Liu X, Harris AD, et al. Transfusion practice in the intensive care unit: a 10-year analysis. Transfusion 2010; 50:2125-2134.